Impact of periprocedural myocardial injury after transcatheter aortic valve implantation on long-term mortality: a meta-analysis of Kaplan-Meier derived individual patient data
Carregando...
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2023
Título da Revista
ISSN da Revista
Título do Volume
Editora
FRONTIERS MEDIA SA
Autores
GAUZA, Mateus de Miranda
RODES-CABAU, Josep
MIEGHEM, Nicolas M. Van
Citação
FRONTIERS IN CARDIOVASCULAR MEDICINE, v.10, article ID 1228305, 8p, 2023
Resumo
Background: Periprocedural myocardial injury (PPMI) frequently occurs after transcatheter aortic valve implantation (TAVI), although its impact on long-term mortality is uncertain.Methods: We performed a pooled analysis of Kaplan-Meier-derived individual patient data to compare survival in patients with and without PPMI after TAVI. Flexible parametric models with B-splines and landmark analyses were used to determine PPMI prognostic value. Subgroup analyses for VARC-2, troponin, and creatine kinase-MB (CK-MB)-defined PPMI were also performed.Results: Eighteen observational studies comprising 10,094 subjects were included. PPMI was associated with lower overall survival (OS) after two years (HR = 1.46, 95% CI 1.30-1.65, p < 0.01). This was also observed when restricting the analysis to overall VARC-2-defined PPMI (HR = 1.23, 95% CI 1.07-1.40, p < 0.01). For VARC-2 PPMI criteria and VARC-2 troponin-only, higher mortality was restricted to the first 2 months after TAVI (HR = 1.64, 95% CI 1.31-2.07, p < 0.01; and HR = 1.32, 95% CI 1.05-1.67, p = 0.02, respectively), while for VARC-2 defined CK-MB-only the increase in mortality was confined to the first 30 days (HR = 7.44, 95% CI 4.76-11.66, p < 0.01).Conclusion: PPMI following TAVI was associated with lower overall survival compared with patients without PPMI. PPMI prognostic impact is restricted to the initial months after the procedure. The analyses were consistent for VARC-2 criteria and for both biomarkers, yet CK-MB was a stronger prognostic marker of mortality than troponin.
Palavras-chave
aortic stenosis, transcatheter aortic valve implantation, transcatheter aortic valve replacement, periprocedural myocardial injury, biomarkers, valvular heart disease, structural heart disease
Referências
- Akodad M, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.118.011111
- Barbash IM, 2013, AM J CARDIOL, V111, P1337, DOI 10.1016/j.amjcard.2012.12.059
- Buse GAL, 2010, EUR J CARDIO-THORAC, V37, P399, DOI 10.1016/j.ejcts.2009.05.054
- Chen WT, 2022, SCAND CARDIOVASC J, V56, P387, DOI 10.1080/14017431.2022.2139412
- Chorianopoulos E, 2014, CLIN RES CARDIOL, V103, P65, DOI 10.1007/s00392-013-0624-8
- Dagan M, 2022, CARDIOVASC REVASCULA, V35, P8, DOI 10.1016/j.carrev.2021.04.006
- De Marzo V, 2021, HEART VESSELS, V36, P1746, DOI 10.1007/s00380-021-01861-8
- Filomena D, 2023, MINERVA CARDIOL ANGI, V71, P77, DOI 10.23736/S2724-5683.21.05630-1
- Généreux P, 2021, J AM COLL CARDIOL, V77, P2717, DOI 10.1016/j.jacc.2021.02.038
- GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515
- Guyot P, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-9
- Guyot P, 2011, VALUE HEALTH, V14, P640, DOI 10.1016/j.jval.2011.01.008
- Haberthür D, 2011, EUR J CARDIO-THORAC, V39, P631, DOI 10.1016/j.ejcts.2010.07.045
- Kahlert P, 2016, EUROINTERVENTION, V11, P1401, DOI 10.4244/EIJY15M05_10
- Kappetein AP, 2012, J AM COLL CARDIOL, V60, P1438, DOI [10.1016/j.jacc.2012.09.001, 10.1093/ejcts/ezs533]
- Kim WK, 2016, CLIN RES CARDIOL, V105, P379, DOI 10.1007/s00392-015-0949-6
- Köhler WM, 2016, CARDIOVASC THER, V34, P385, DOI 10.1111/1755-5922.12208
- Koifman E, 2017, AM J CARDIOL, V120, P850, DOI 10.1016/j.amjcard.2017.05.059
- Koskinas KC, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.002430
- Liu N, 2021, BMC MED RES METHODOL, V21, DOI 10.1186/s12874-021-01308-8
- Michail M, 2018, CIRC-CARDIOVASC INTE, V11, DOI 10.1161/CIRCINTERVENTIONS.118.007106
- Michiels S, 2005, INT J TECHNOL ASSESS, V21, P119, DOI 10.1017/S0266462305050154
- Moher D., 2009, PLOS MED, V6
- Nara Y, 2018, INT HEART J, V59, P1296, DOI 10.1536/ihj.17-645
- Otto CM, 2021, CIRCULATION, V143, pe72, DOI [10.1161/CIR.0000000000000923, 10.1016/j.jacc.2020.11.018, 10.1161/CIR.0000000000001030]
- Palmerini Tullio, 2023, JACC Cardiovasc Interv, V16, P396, DOI 10.1016/j.jcin.2022.12.009
- Rahhab Z, 2019, STRUCT HEART, V3, P431, DOI 10.1080/24748706.2019.1639234
- Real C, 2023, JACC-CARDIOVASC INTE, V16, P1221, DOI 10.1016/j.jcin.2023.03.022
- Ribeiro HB, 2015, J AM COLL CARDIOL, V66, P2075, DOI 10.1016/j.jacc.2015.08.881
- Ribeiro HB, 2015, EUROINTERVENTION, V11, P205, DOI 10.4244/EIJV11I2A39
- Ribeiro HB, 2015, ANN THORAC SURG, V99, P2001, DOI 10.1016/j.athoracsur.2015.01.029
- Rodés-Cabau J, 2011, J AM COLL CARDIOL, V57, P1989, DOI 10.1016/j.jacc.2010.11.060
- Royston P, 2002, STAT MED, V21, P2175, DOI 10.1002/sim.1203
- Schindler M, 2021, J AM HEART ASSOC, V10, DOI 10.1161/JAHA.120.020739
- Sharma V, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.118.011889
- Sinning JM, 2016, EUROINTERVENTION, V11, P1522, DOI 10.4244/EIJY15M02_02
- Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919
- Stundl A, 2017, JACC-CARDIOVASC INTE, V10, P1550, DOI 10.1016/j.jcin.2017.05.029
- Takagi H, 2020, J CARDIOVASC SURG, V61, P98, DOI 10.23736/S0021-9509.19.11023-3
- Vahanian A, 2022, EUROINTERVENTION, V17, pE1126, DOI [10.1093/eurheartj/ehab395, 10.4244/EIJ-E-21-00009]
- Wei YH, 2017, STATA J, V17, P786, DOI 10.1177/1536867X1701700402
- Yong ZY, 2012, CIRC-CARDIOVASC INTE, V5, P415, DOI 10.1161/CIRCINTERVENTIONS.111.964882